InterOme, Inc., Carlsbad, CA 92008, USA.
Center for Microbiome Innovation, University of California San Diego, La Jolla, CA 92093, USA.
Crit Rev Immunol. 2021;41(6):27-42. doi: 10.1615/CritRevImmunol.2022043153.
The impact of the human microbiome, the diverse collection of microorganisms that inhabit nearly every niche in the human body, in shaping the immune response to dysbiotic events is apparent if poorly understood, particularly in complex, evolving disease states such as breast cancer. The impacts can be both indirect via metabolites and immune-interactions along the skin, gut, and oral cavities where the microbial communities are most abundant, or direct in the tumor microenvironment where microbial activities can promote growth or clearance of cancerous cells. Based on reports of using gut microbial signatures to predict therapeutic efficacy, the role that gut microbes and their metabolites may play in shaping the success or failure of immunotherapy has been extensively reviewed. In this review, we dissect the evidence for the direct and distal impact of microbes on oncogenesis, tumor growth and the immune responses to combat or promote tolerance of breast cancer tumors. Implementation of robust, valid analyses and methods are lacking in the field, and we provide recommendations for researchers and clinicians to work together to characterize the micro-biome-immune-breast cancer interactions that will hopefully enable the next generation of biomarkers and targets for improving disease outcomes.
人体微生物组是指栖息在人体几乎每一个生态位的多种微生物的集合,其对免疫反应的影响在形成肠道菌群失调事件中是显而易见的,但目前人们对此了解甚少,尤其是在乳腺癌等复杂的、不断演变的疾病状态中。这种影响可能是间接的,通过皮肤、肠道和口腔中微生物群落最丰富的代谢物和免疫相互作用来实现,也可能是直接的,在肿瘤微环境中,微生物的活动可以促进癌细胞的生长或清除。基于使用肠道微生物特征来预测治疗效果的报告,肠道微生物及其代谢物在塑造免疫疗法成败方面的作用已经被广泛研究。在这篇综述中,我们剖析了微生物对肿瘤发生、肿瘤生长以及免疫反应的直接和间接影响,以对抗或促进乳腺癌肿瘤的耐受性。该领域缺乏强有力的、有效的分析和方法,我们为研究人员和临床医生提供了建议,以共同研究微生物组-免疫-乳腺癌相互作用,希望这将为改善疾病预后提供下一代生物标志物和治疗靶点。